Seeking Alpha

Leonard Yaffe's  Instablog

Leonard Yaffe
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
View Leonard Yaffe's Instablogs on:
  • NASH Is The New Hep C

    One of my focus areas has been hepatology, especially Hepatitis C and NASH. Regarding the latter, investors have focused primarily on Intercept Pharmaceuticals (ICPT, market cap. $4.8 billion), and to a lesser extent on Genfit (GNFT, market cap. $1.2 Billion). Gilead has been given very little credit for its drug, simtuzumab. On the more speculative investment side, Galectin Therapeutics (GALT, market cap. $300 million) is in phase 1 with its lead drug GR-MD-02, a galectin-3 inhibitor. This drug may be effective in treating more severe forms of NASH, which is extremely valuable from a pharmacoeconomic perspective. The company will be hosting a conference call Tuesday morning to discuss Phase 1 data. This company has excellent management and is targeting the appropriate patient population.


    Disclosure: The author is long ICPT, GILD, GALT, GNFTF.

    Tags: ICPT, GILD, GALT
    Jul 25 10:57 AM | Link | 12 Comments
  • GILD---The Train Has Finally Left The Station

    After a severe correction in the Spring (along with the rest of the high-growth pharmaceutical sector), GILD has broken through the $84 resistance level and is making new all-time highs on almost a daily basis. Despite this run up, the stock remains incredibly attractive (more so than any other similarly misclassified "biotech"), trading at less than 11x 2015E EPS, with a forward growth rate of 18%. The argument as to the size of the Hepatitis C drug market is largely resolved but still underestimated, and so to that concerning the duration of significant sales. I would not be short this stock for the expectation of a price war, especially as I expect Gilead's FDC to be priced at a "course of therapy" discount to current regimens (both reflecting a shorter medication period and less use of other drugs). While I believe that, time of introduction independent, Merck has the next best regimen, I maintain that the market is sufficiently large for both companies to do extremely well. In my opinion, the near-term losers are JNJ (Olysio should largely disappear) and Roche (it should have become a factor), with AbbVie unlikely to garner significant share.

    Near term, Gilead's earnings will be driven by its Hepatitis C franchise. Over the intermediate term, and largely absent from discussion, its earnings will be augmented by its research and development efforts in oncology, hepatology and nephrology, as well as its TAF program in HIV.

    Gilead is scheduled to report Q2 results next week, and while I expect them to readily exceed expectations, this is "only the beginning". Q3 results should reflect additional patient warehousing ahead of the FDC launch, whereas Q4 results (as well as Q1'15) should be awesome. The upcoming Q3 warehousing is a known phenomenon, and should not be used as a reason to avoid the stock. My target price remains $140.


    Disclosure: The author is long GILD.

    Tags: GILD
    Jul 14 6:13 PM | Link | 5 Comments
  • Healthcare Stocks Start Off Q3 Strong

    During early Q2, there was significant pressure on mid-cap pharmaceutical (aka "biotech", though a misnomer) stocks, resulting in under-ownership and excess shorting. With that pressure now relieved, investor attention has returned. I continue to believe that GILD is the most attractive pharmaceutical stock, followed by MRK. Corollary beneficiaries of the tremendous growth in Hepatitis C treatment include OSUR and CBM. On the supply side, I continue to recommend stocks of commodity medical companies involved with products and injectable drugs . All the best, Len

    Disclosure: The author is long GILD, MRK, OSUR, CBM.

    Tags: GILD, MRK, OSUR, CBM
    Jul 04 5:10 PM | Link | Comment!
Full index of posts »
Latest Followers


  • $GILD Gilead Anthem deal, if no patient exclusions (ie fibrosis stage), is another example of trading volume for price. Win-win. BUY GILD
    Jan 8, 2015
  • Is There A New Reality To The Drug Industry?
    Dec 23, 2014
  • Update: News On Gilead From The California Technology Assessment Forum $GILD
    Dec 19, 2014
More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.